In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivelix Pharmaceuticals, Ltd.

http://vivelix.com/

Latest From Vivelix Pharmaceuticals, Ltd.

InDex To Fly Solo With Ulcerative Colitis Drug In US

Approval is unlikely before 2027 but Sweden’s InDex has done the maths and decided that it can launch cobitolimod across the Atlantic on its own with a staff of around 100.

Launches Gastrointestinal

Finance Watch: Four Biotech VC Funds Raise $1.7bn Combined

Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline. 

Finance Watch StartUps and SMEs

Deals Shaping the Medical Industry, December 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.

Deals BioPharmaceutical

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
UsernamePublicRestriction

Register